Effects of pooled platelet concentrate after coronary artery bypass graft surgery in patients with dual antiplatelet therapy: a clinical investigation

Kaya K., Mungan U.

TEXAS HEART INSTITUTE JOURNAL, vol.50, no.1, pp.10-15, 2023 (SCI-Expanded)

  • Publication Type: Article / Article
  • Volume: 50 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.14503/thij-22-7864
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.10-15
  • Lokman Hekim University Affiliated: Yes



Dual antiplatelet therapy has become standard in the first-line treatment of acute

coronary syndromes, but it increases the risk of bleeding complications. We aimed to

investigate pooled platelet concentrate's benefits in reducing postoperative bleeding in

patients undergoing off-pump coronary artery bypass surgery after a dual antiplatelet

drug loading dose.


One hundred nine patients who underwent emergent coronary artery bypass surgery

within the first 24 hours after being given dual antiplatelet therapy loading dose were

included in the study and divided into two groups; patients who were given pooled

platelet concentrate during the surgery (Group 1, n=63), and patients who were not

provided (Group 2, n=46). The amount of bleeding in the postoperative period and the

need for blood transfusions were recorded.


The surgical drainage amounts were 475.39±101.94 ml in Group 1 and 679.34±232.03

ml in Group 2 (p=0.001). The need for surgical revisions was 0% and 15.2% in Group 1

and Group 2, respectively (p=0.002). The duration of hospitalization after surgery was

4 (4-6) days in Group 1 and 6 (4-9) days in Group 2 (p=0.001). Total transfusions per

patient werehigher in Group 2 than in Group 1 (1 (1-4) units and 3 (2-7) units,

respectively, p=0.001).


Using perioperative pooled platelet concentrate in patients with dual antiplatelet

therapy reduces postoperative bleeding, and the need for all kinds of blood products,

and shortens the hospital stay. As a result,